Do neurocysticercosis-related seizures lead to epilepsy and what is the long-term impact of treatment?

Neurocysticercosis, an infection of the brain with pork tapeworm larvae, is highly endemic in Sub-Saharan Africa, Latin America, and Asia, and increasingly common in developed countries like the U.S. due to immigration. The larvae form cysts in the brain, which can cause a variety of neurological symptoms, seizures being the most common. Previous literature has suggested that neurocysticercosis is an important cause of epilepsy in developing countries where it is endemic. The standard treatment for neurocysticercosis is antiparasitic medication, such as albendazole, although it does not kill the parasite in all patients.

A new study led by Associate Professor Elizabeth Kelvin together with Assistant Professor Hongbin Zhang, MPH graduate Mindy Chang, and DPH student Matthew Romo explores the complex relationship between albendazole treatment for neurocysticercosis and long-term seizure outcomes. The study was published in the journal Epilepsia.

The researchers used data from a randomized controlled trial comparing newly diagnosed neurocysticercosis patients treated with albendazole versus placebo. They found that that the relationship between albendazole and seizures over 24 months changed over time, with an initial reduction of seizures among those treated with the drug but little difference and even reversal of the association over time. Furthermore, the treatment impact on seizures was mediated by drug-related changes in the parasitic cysts over time. Once the cysts completely resolve, seizures stop, suggesting that seizures associated with neurocysticercosis are acute symptomatic seizures and not epilepsy, as many have called it, Kelvin says.

Further long-term follow-up studies to understand the relationship between neurocysticercosis-related symptoms and the evolution of the encysted parasites over time are needed in order to better treat these patients.

For more information, contact:
Elizabeth Kelvin
[email protected]
646-364-9622

About the Institute for Implementation Science in Population Health 
The CUNY Institute for Implementation Science in Population Health (ISPH) was founded on the notion that substantial improvements in population health can be efficiently achieved through better implementation of existing strategies, policies, and interventions across multiple sectors. We study how to translate and scale-up evidence-based interventions and policies within clinical and community settings in order to improve population health and reduce health disparities. CUNY ISPH. Pursing population health gains through better implementation. www.cunyisph.org. Follow us on Twitter: @CUNYISPH.

About the CUNY Graduate School of Public Health and Health Policy
The CUNY Graduate School of Public Health and Health Policy (CUNY SPH) is committed to teaching, research and service that creates a healthier New York City and helps promote equitable, efficient and evidence-based solutions to pressing health problems facing cities around the world. For more information, visit sph.cuny.edu.

Citation: “Exploring the complex associations over time among albendazole treatment, cyst evolution, and seizure outcomes in neurocysticercosis,” Arturo Carpio, Mindy Chang, Hongbin Zhang, Matthew L. Romo, Alex Jaramillo, W. Allen Hauser, Elizabeth A. Kelvin, Epilepsia, July 29, 2019, 2019;00:1–9. doi: 10.1111/epi.16302